{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:48:15Z","timestamp":1740178095495,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Indonesia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s41669-023-00401-6","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T09:02:25Z","timestamp":1684573345000},"page":"605-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0980-5986","authenticated-orcid":false,"given":"Cesarius Singgih","family":"Wahono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-674X","authenticated-orcid":false,"given":"Laniyati","family":"Hamijoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriawati","family":"Hendrawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyana","family":"Rakinaturia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabal","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Isbagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"401_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"401_CR2","unstructured":"Indonesia PR. Diagnosis dan pengelolaan spondiloartritis. Perhimpunan Reumatologi Indonesia; 2021 [Internet] https:\/\/reumatologi.or.id\/rekomendasi-diagnosis-dan-pengelolaan-spondiloartritis-2021\/. Accessed 10 July 2021."},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/1756-185X.13635","volume":"22","author":"D Kim","year":"2019","unstructured":"Kim D, Kim H, Cho S, Park MC. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective. Int J Rheum Dis. 2019;22:1630\u20137.","journal-title":"Int J Rheum Dis"},{"key":"401_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5152\/eurjrheum.2018.18162","volume":"5","author":"WP Maksymowych","year":"2018","unstructured":"Maksymowych WP, Strand V, Nash P, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol. 2018;5:216\u201323.","journal-title":"Eur J Rheumatol"},{"key":"401_CR5","doi-asserted-by":"crossref","unstructured":"Maksymowych WP, Choy E, Yazici Y, Walsh JA, Thom H, Kalyvas C, Fox T, Gandhi K, Jugl S. Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). [Internet] https:\/\/acrabstracts.org\/abstract\/comparative-effectiveness-of-secukinumab-and-golimumab-in-ankylosing-spondylitis-assessed-by-matching-adjusted-indirect-comparison-using-pivotal-phase-3-clinical-trial-data\/. Accessed 5 June 2022.","DOI":"10.1136\/annrheumdis-2017-eular.5850"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Secukinumab: A review in ankylosing spondylitis. Drugs. 2019;79:433\u201343.","journal-title":"Drugs"},{"key":"401_CR7","unstructured":"Phillippo DM AA, Dias S, Palmer S, Abrams KR, Welton NJ . Nice dsu technical support document 18: Methods for population-adjusted indirect comparisons in submission to nice, 2016 [Internet] https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj. Accessed 7 Apr 2021."},{"key":"401_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"401_CR9","doi-asserted-by":"publisher","first-page":"A100","DOI":"10.1016\/j.jval.2016.03.1723","volume":"19","author":"H Thom","year":"2016","unstructured":"Thom H, Jugl S, Palaka E, Sunil J. Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. Value Health. 2016;19:A100\u2013A101. https:\/\/doi.org\/10.1016\/j.jval.2016.03.1723.","journal-title":"Value Health."},{"key":"401_CR10","unstructured":"INDONESIA CSOTRO. Statistics Indonesia releases 2020 census results. 2021 [Internet]; https:\/\/setkab.go.id\/en\/statistics-indonesia-releases-2020-census-results\/#:~:text=Statistics%20Indonesia%20(BPS)%20has%20released,141%20people%20per%20square%20kilometer.&text=Based%20on%20the%20distribution%20per,on%20the%20island%20of%20Java. Accessed 7 Apr 2021."},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","volume":"56","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017;56:95\u2013102.","journal-title":"Rheumatology (Oxford)"},{"key":"401_CR12","unstructured":"AbbVie Biotechnology GmbH & Co KG. L, Germany. Fraizeron product information 2019; adalimumab summary of product characteristics. 2019 [Internet] http:\/\/pionas.pom.go.id\/obat-baru\/humira-larutan-injeksi-40-mg08-ml. Accessed 7 Apr 2021."},{"key":"401_CR13","unstructured":"Novartis. Fraizeron\u00ae (secukinumab) 150 mg powder for solution for injection basic succinct statement (bss). 2020 [Internet] https:\/\/www.mims.com\/indonesia\/drug\/info\/fraizeron?type=full. Accessed 12 May 2021."},{"key":"401_CR14","unstructured":"MIMS. Infliximab generic medicine info 2020 [Internet] https:\/\/www.mims.com\/indonesia\/drug\/info\/infliximab. Accessed 10 July 2021."},{"key":"401_CR15","unstructured":"MIMS. Golimumab generic medicine info. 2021 [Internet] https:\/\/www.mims.com\/indonesia\/drug\/info\/golimumab?mtype=generic. Accessed 12 May 2021."},{"key":"401_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111.","journal-title":"Arthritis Res Ther"},{"key":"401_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/1744666X.2019.1561281","volume":"15","author":"S Dubash","year":"2019","unstructured":"Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H. The advent of il-17a blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol. 2019;15:123\u201334.","journal-title":"Expert Rev Clin Immunol"},{"key":"401_CR18","doi-asserted-by":"publisher","first-page":"32768","DOI":"10.1038\/srep32768","volume":"6","author":"W Liu","year":"2016","unstructured":"Liu W, Wu YH, Zhang L, et al. Efficacy and safety of tnf-\u03b1 inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. Sci Rep. 2016;6:32768.","journal-title":"Sci Rep"},{"key":"401_CR19","first-page":"A555","volume":"20","author":"A Patino","year":"2017","unstructured":"Patino A, Karpf E. Secukinumab as a more efficient alternative for the treatment of ankylosing spondylitis: a cost per responder analysis versus adalimumab and golimumab from a peruvian perspective for private and public health schemes. Value Health. 2017;20:A555.","journal-title":"Value Health"},{"key":"401_CR20","first-page":"A555","volume":"20","author":"A Patino","year":"2017","unstructured":"Patino A, Karpf E. Secukinumab as a more efficient alternative for the treatment of ankylosing spondylitis: A cost per responder analysis versus adalimumab and golimumab from a colombian perspective. Value Health. 2017;20:A555.","journal-title":"Value Health"},{"key":"401_CR21","doi-asserted-by":"publisher","first-page":"A537","DOI":"10.1016\/j.jval.2016.09.1108","volume":"19","author":"P Gunda","year":"2016","unstructured":"Gunda P, Kandhare A, Nikoglou E, Jugl SM, Kneidl J, Neidhardt K. A cost per responder analysis of secukinumab vs adalimumab based on a matching-adjusted indirect comparison for the treatment of ankylosing spondylitis from a german payer perspective. Value Health. 2016;19:A537.","journal-title":"Value Health"},{"key":"401_CR22","unstructured":"Walsh J, Nikoglou E, Praveen G, Park Y, Jugl S. Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). [Internet] https:\/\/acrabstracts.org\/abstract\/secukinumab-vs-adalimumab-for-the-treatment-of-ankylosing-spondylitis-a-cost-per-responder-analysis-at-52-weeks-from-the-us-perspective\/. Accessed 5 June 2022."},{"key":"401_CR23","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jval.2018.07.609","volume":"21","author":"H Al Mudaiheem","year":"2018","unstructured":"Al Mudaiheem H, Al Howimel M, Al Jufan K, et al. Cost per-responder analysis of secukinumab compared to adalimumab for the treatmenmt of ankylosing spondylitis over one year in saudi arabia. Value Health. 2018;21:S81\u20132.","journal-title":"Value Health"},{"key":"401_CR24","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Van der Heijde","year":"2009","unstructured":"Van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the atlas trial. Ann Rheum Dis. 2009;68:922\u20139.","journal-title":"Ann Rheum Dis"},{"key":"401_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase iii study. Arthritis Care Res (Hoboken). 2017;69:1020\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"401_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.24001","volume":"59","author":"J Braun","year":"2008","unstructured":"Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270\u20138.","journal-title":"Arthritis Rheum"},{"key":"401_CR27","unstructured":"Kesehatan K. Peraturan menteri kesehatan tentang perubahan atas peraturan menteri kesehatan nomor 52 tahun 2016 tentang standar tarif pelayanan kesehatan dalam penyelenggaraan program jaminan kesehatan. 2016 [Internet]. https:\/\/peraturan.bpk.go.id\/Home\/Details\/114477\/permenkes-no-64-tahun-2016. Accessed 15 Mar 2022."},{"key":"401_CR28","unstructured":"WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin-resistant TB (MDR\/RR-TB), 2021\u20132025 [Internet]. https:\/\/apps.who.int\/iris\/handle\/10665\/341980. Accessed 5 June 2022."},{"key":"401_CR29","doi-asserted-by":"publisher","first-page":"1759720x2093011","DOI":"10.1177\/1759720X20930116","volume":"12","author":"G Evangelatos","year":"2020","unstructured":"Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic dmards, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020;12:1759720x20930116.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"401_CR30","doi-asserted-by":"publisher","first-page":"e001280","DOI":"10.1136\/rmdopen-2020-001280","volume":"6","author":"B Michelsen","year":"2020","unstructured":"Michelsen B, Lindstr\u00f6m U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020;6(3):e001280. https:\/\/doi.org\/10.1136\/rmdopen-2020-001280.","journal-title":"RMD Open"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00401-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:13:33Z","timestamp":1688980413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00401-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00401-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"19 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Novartis Indonesia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Source"}},{"value":"CS Wahono, L Hamijoyo, and H Isbagio were contracted by Novartis Indonesia for the study. Y Hendrawan and L Rakinaturia are employees of Novartis Indonesia. N Mittal, P Khanna, and M Jain are employees of Novartis Healthcare Private Limited, Hyderabad, India.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from patients\/participants)"}},{"value":"All data generated or analysed during the study are included in this published article and its supplementary files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The model used in this study was provided to the journal\u2019s peer reviewers for their reference when reviewing the manuscript. Codes are embedded in the model.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were involved in conducting the study. All authors commented on all versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution Statement"}}]}}